U.S. Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), and Others), Product (Software and Device), and Sales Channel (Business-to-Business(B2B), Business-to-Consumer (B2C)): Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4058965
- 139 Pages
- August 2020
- Healthcare
Digital therapeutics provides evidence-based therapeutic interventions to patients. It is driven by software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. These products incorporate advanced technology, best practices regarding the design, usability, clinical validation, and data security. These products are reviewed and approved by regulatory bodies before use. Furthermore, digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Increase in adoption of smartphones and tablets coupled with healthcare apps, growth in need to control healthcare cost, and rise in incidence of chronic diseases drive the growth of the U.S. digital therapeutics market. However, lack of awareness regarding digital therapeutics and patient data privacy concerns restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 19.2% from 2020 to 2027. On the contrary, favorable laws and regulations for digital health technology and increase in investments in digital therapeutics are anticipated to offer significant growth opportunities for the market players in the future.
The U.S. digital therapeutics market is segmented into application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employer & payer, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current U.S. digital therapeutics market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate country-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the U.S. digital therapeutics market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
• By Application
o Diabetes
o Obesity
o Cardiovascular Disease (CVD)
o Central Nervous System (CNS) Disease
o Respiratory Disease
o Smoking Cessation
o Gastrointestinal Disorder (GID)
o Others
• By Product
o Software
o Device
• By Sales Channel
o Business-to-Business (B2B)
Employer and Payer
Healthcare Provider
Others
o Business-to-Consumer (B2C)
Patient
Caregiver
KEY MARKET PLAYERS
• 2MORROW, Inc.
• Fitbit, Inc. (Twine Health, Inc.)
• Livongo Health, Inc.
• Medtronic Plc.
• Omada Health, Inc.
• Pear Therapeutics, Inc.
• Proteus Digital Health, Inc.
• Resmed, Inc. (Propeller Health)
• Voluntis, Inc.
• Welldoc, Inc.
The other players in the value chain include (profiles not included in the report):
• Canary Health Inc.
• Mango Health Inc.
• Noom, Inc.
• Dthera Sciences
1.1.Report description
1.2.Key benefits for stakeholders
1.3.key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top Player Positioning, 2019
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in adoption of smartphones, tablets, and smart wearables, coupled with healthcare apps
3.5.1.2.Urge in need to control healthcare costs
3.5.1.3.Rise in prevalence of chronic diseases
3.5.1.4.Growth in adoption of advanced technologies and tech-driven healthcare products & applications
3.5.2.Restraints
3.5.2.1.Lack of reimbursement policies for digital therapeutics
3.5.2.2.Patient data privacy concerns
3.5.3.Opportunity
3.5.3.1.Favorable laws and regulations for digital health technology
3.5.3.2.Increase in investments in digital therapeutics
3.6.Impact analysis of COVID-19 on the U.S. digital therapeutics market
CHAPTER 4:DIGITAL THERAPEUTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Diabetes
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.3.Obesity
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.4.Cardiovascular diseases
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.5.Central nervous system (CNS) diseases
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast
4.6.Gastrointestinal disorder
4.6.1.Key market trends and growth opportunities
4.6.2.Market size and forecast
4.7.Respiratory diseases
4.7.1.Key market trends and growth opportunities
4.7.2.Market size and forecast
4.8.Smoking cessation
4.8.1.Key market trends and growth opportunities
4.8.2.Market size and forecast
4.9.Others
4.9.1.Key market trends and growth opportunities
4.9.2.Market size and forecast
CHAPTER 5:DIGITAL THERAPEUTICS MARKET, BY PRODUCT
5.1.Overview
5.1.1.Market size and forecast
5.2.Software
5.2.1.Market size and forecast
5.3.Devices
5.3.1.Market size and forecast
CHAPTER 6:DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Business-To-Business (b2b)
6.2.1.Market size and forecast, by type
6.2.2.Employer and Payer
6.2.2.1.Market size and forecast
6.2.3.Healthcare Providers
6.2.3.1.Market size and forecast
6.2.4.Others
6.2.4.1.Market size and forecast
6.3.Business-to-consumers
6.3.1.Market size and forecast, by type
6.3.2.Patients
6.3.2.1.Market size and forecast
6.3.3.Caregivers
6.3.3.1.Market size and forecast
CHAPTER 7:COMPANY PROFILES
7.1.2MORROW, INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Key strategic moves and developments
7.2.FITBIT, INC. (TWINE HEALTH, INC.)
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments
7.3.LIVONGO HEALTH, INC.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Product portfolio
7.3.4.Business performance
7.3.5.Key strategic moves and developments
7.4.MEDTRONIC PLC.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.PEAR THERAPEUTICS, INC.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Key strategic moves and developments
7.6.OMADA HEALTH, INC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Key strategic moves and developments
7.7.PROTEUS DIGITAL HEALTH, INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Key strategic moves and developments
7.8.RESMED, INC. (PROPELLER HEALTH)
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.VOLUNTIS, INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.WELLDOC, INC.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments
TABLE 01.U.S. DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 02.SMART PILLS FOR CAPSULE ENDOSCOPY, DRUG DELIVERY, AND PATIENT MONITORING AVAILABLE IN THE MARKET
TABLE 03.U.S. DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 05.U.S. DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 06.U.S. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2019–2027 ($MILLION)
TABLE 07.U.S. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2019–2027 ($MILLION)
TABLE 08.2MORROW: COMPANY SNAPSHOT
TABLE 09.2MORROW: PRODUCT PORTFOLIO
TABLE 10.FITBIT: COMPANY SNAPSHOT
TABLE 11.FITBIT: PRODUCT PORTFOLIO
TABLE 12.LIVONGO: COMPANY SNAPSHOT
TABLE 13.LIVONGO: PRODUCT PORTFOLIO
TABLE 14.MEDTRONIC: COMPANY SNAPSHOT
TABLE 15.MEDTRONIC: OPERATING SEGMENTS
TABLE 16.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 17.PEAR: COMPANY SNAPSHOT
TABLE 18.PEAR: PRODUCT PORTFOLIO
TABLE 19.OMADA: COMPANY SNAPSHOT
TABLE 20.OMADA: PRODUCT PORTFOLIO
TABLE 21.PROTEUS: COMPANY SNAPSHOT
TABLE 22.PROTEUS: PRODUCT PORTFOLIO
TABLE 23.RESMED: COMPANY SNAPSHOT
TABLE 24.RESMED: OPERATING SEGMENTS
TABLE 25.RESMED: PRODUCT PORTFOLIO
TABLE 26.VOLUNTIS: COMPANY SNAPSHOT
TABLE 27.VOLUNTIS: OPERATING SEGMENTS
TABLE 28.VOLUNTIS: PRODUCT PORTFOLIO
TABLE 29.WELLDOC: COMPANY SNAPSHOT
TABLE 30.WELLDOC: PRODUCT PORTFOLIO
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
